{"entity":{"id":"nct06425302","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","aka":["GOLSEEK-2"],"tldr":"A phase 2 trial of Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in non-Hodgkin lymphoma, run by Celgene, active and no longer recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma is a phase 2 interventional study registered as NCT06425302 by Celgene, with 95 participants enrolled, started 2024-08-30 and due to reach its primary completion in 2026-06-19. Interventions recorded: Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06425302","url":"https://clinicaltrials.gov/study/NCT06425302"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","follicular-lymphoma"],"sections":[],"technologies":["monoclonal-antibody","protac-degrader"],"targets":[],"drugs":["golcadomide","rituximab","cyclophosphamide","doxorubicin","vincristine","prednisone"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06425302","phase":"2","setting":"A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","sponsor":"Celgene","started":"2024-08-30","startedType":"actual","enrolled":95,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06425302/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}